About US
Contact us
-
Obama's re-elected. So what's next for pharma?To call the 2012 election a referendum on Obamacare would be reductionist. But the Affordable Care Act's survival is, no question, the most obvious and specific consequence of President Obama's re-2012/11/8
-
Lundbeck earnings undercut by Lexapro declineDanish drugmaker Lundbeck, whose Lexapro sales have been depressed by generics, managed to maintain a flat operating profit in its third quarter as it works on a potential new blockbuster in hopes2012/11/8
-
Pfizer nabs FDA blessing for blockbuster hopeful XeljanzIt's a banner day for Pfizer ($PFE): The drugmaker's new rheumatoid arthritis drug tofacitinib, one of its leading hopes for sales growth, finally won its approval from the FDA. Now dubbed Xeljanz,2012/11/7
-
Drug offers new pain management therapy for diabeticsA study from the University of Calgary's Hotchkiss Brain Institute shows there is evidence to support a new drug therapy called nabilone to treat diabetic neuropathy, or nerve pain. Researchers enroll2012/11/7
-
FDA backs Pradaxa safety as docs lament lack of antidoteFDA has sifted the data on Pradaxa, the blood thinner that's attracted some controversy of late. And despite an onslaught of adverse-event reports--and hundreds of deaths--the agency says rates2012/11/6
-
Construction to begin on world's largest chromatography labNovasep will build the world's largest chromatography plant for drug development in the French town of Mourenx. Announcing its plans, the life sciences manufacturer said it would put 30 million euros2012/11/6
-
UK spending on new medicines is fallingThe NHS in England is spending increasingly less on innovative new medicines, an industry expert has revealed. A recent report from OHE Consulting, compiled on behalf of the Association of the Britis2012/11/5
-
Report recommends patient-centric approach to encourage adherenceMany patients fail to adhere to their treatment regimes, losing national health care industries billions of pounds every year. A new report by Cutting Edge Information claims that one of the best way2012/11/5
-
Visterra to present efficacy data on VIS410 against H5N1 influenzaVisterra has announced that it will be presenting prophylactic and therapeutic efficacy data for VIS410 in the treatment of the H5N1 (Avian Flu) strain of influenza at a conference in Vietnam. The co2012/11/2
-
Shionogi to take 10pc stake in GSK HIV drugJapanese pharmaceutical group Shionogi is to receive a ten per cent stake in ViiV Healthcare, a joint venture between GlaxoSmithKline (GSK) and Pfizer. Under the terms of the deal, ViiV will acquire2012/11/2